EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY-NC 4.0

Safety and efficacy of ibrutinib in a patient with severe renal impairment

Kalman Filanovsky, Lev Shvidel

Hematology Reports · 2017

DOI: 10.4081/hr.2017.7078 ↗

Kurz gefasst

Editorial in der Zeitschrift Hematology Reports, 2017. Verfasst von Kalman Filanovsky und 1 weiteren Autor:innen. Beteiligte Einrichtung: Kaplan Medical Center, Rehovot; Hadassah and Hebrew University Medical School, Jerusalem, Israel. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Not available

Schlagwörter

Stichwörter der Autor:innen

chronic renal failureibrutiniblymphoma

Autor:innen und Institutionen

  • Kaplan Medical Center, Rehovot; Hadassah and Hebrew University Medical School, Jerusalem, Israel.

Zitieren

APA

Filanovsky, K., & Shvidel, L. (2017). Safety and efficacy of ibrutinib in a patient with severe renal impairment. Hematology Reports. https://doi.org/10.4081/hr.2017.7078

Vancouver

Filanovsky K, Shvidel L. Safety and efficacy of ibrutinib in a patient with severe renal impairment. Hematology Reports. 2017. doi:10.4081/hr.2017.7078

BibTeX
@article{Filanovsky2017,
  author = {Filanovsky, Kalman and Shvidel, Lev},
  title = {Safety and efficacy of ibrutinib in a patient with severe renal impairment},
  journal = {Hematology Reports},
  year = {2017},
  doi = {10.4081/hr.2017.7078}
}
Kostenlos starten →